CBAS Heparin Surface

See the technology

Gore’s CBAS Heparin Surface, the proven heparin bonding technology for lasting thromboresistance, is used in many of our interventional and vascular surgery products. End-point covalent bonding keeps heparin anchored to the device, while the bioactive site remains free to interact with the blood to help prevent clotting.*

  • Proven heparin availability: Performance-ready heparin active site1,4*
  • Proven heparin bioactivity: Unmatched, persistent ability to take up antithrombin2,3*
  • Proven lasting thromboresistance: Improved surface hemocompatibility resulting from heparin availability and bioactivity1,2,3,4,5*

*See full CBAS Heparin Surface references

CBAS is a trademark of Carmeda AB, a wholly owned subsidiary of W. L. Gore & Associates, Inc.

Featured Gore Products with CBAS Heparin Surface

propaten-CBAS-cardimg

50% reduction in the risk of graft occlusion compared to standard ePTFE in Critical Limb Ischemia (CLI) patients 1
 

Learn more >


1. Lindholt JS, Gottschalksen B, Johannesen N, et al. The Scandinavian Propaten® Trial – 1-year patency of PTFE vascular prostheses with heparin-bonded luminal surfaces compared to ordinary pure PTFE vascular prostheses – a randomised clinical controlled multi-centre trial. European Journal of Vascular & Endovascular Surgery 2011;41(5):668-673.

 

 

 

 

 

propaten-CBAS-cardimg-2

The GORE® TIGRIS® Vascular Stent features Gore's CBAS Heparin Surface, designed to resist thrombus formation, a problem common in both bare metal and drug-eluting stents.
 

LEARN MORE >

propaten-CBAS-cardimg-3

An Investigational Device Exemption (IDE) Clinical Study of the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface** in Japan demonstrated:

  • 88% 12-month primary patency in long, complex SFA lesions (n = 103)1
  • 21.8 cm average lesion length
  • 65.7% chronic total occlusions (CTOs)
  • 84.5% TASC II C&D lesions

 

Learn more >


** Heparin Bioactive Surface is synonymous with the CBAS Heparin Surface.

1. GORE® VIABAHN® Endoprosthesis Japan IDE Clinical Study demonstrated 12-month primary patency of 92% as defined by evidence of flow with no Target Lesion Revascularization (TLR). The same study demonstrated 88% 12-month primary patency when defined by PSVR of < 2.5 without a TLR.